TrialMultiple sclerosis (Houndmills, Basingstoke, England)2012

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Christian Confavreux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.